Literature DB >> 17852458

Erythrocyte CD38 as a prognostic marker in cancer.

Isil Albeniz1, Ozlem Demir, Leyla Türker-Sener, Leman Yalçintepe, Rüstem Nurten, Engin Bermek.   

Abstract

BACKGROUND: Surface antigen CD38 which is a multifunctional protein with enzymatic and receptorial properties is involved in many processes of cell proliferation and activation. It is widely expressed within the hematopoetic system, and its expression is stimulated by proinflammatory cytokines. CD38-associated enzymatic activities in erythrocytes from cancer patients were investigated in this context.
METHODS: Erythrocyte NAD glycohydrolase and ADP-ribosyl cyclase activities in normal individuals and cancer patients were compared and correlation of these activities to CEA values and anemia were determined. Changes in CD38-expression were followed by SDS-PAGE and Western blot analysis of erythrocyte membrane proteins.
RESULTS: Erythrocyte NAD glycohydrolase and ADP-ribosyl cyclase activities were significantly increased in cancer, in parallel to enhancement of CD38 expression and in correlation with CEA values and anemia.
CONCLUSIONS: An increased expression of CD38 which may be due to action of proinflammatory cytokines produced in tumor-host reactions appears to account for the elevations in erythrocyte CD38-associated enzyme activities in cancer patients. The changes in these enzyme activities may provide a prognostic outlook in view of their apparently close correlation to tumor progressions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17852458     DOI: 10.1080/10245330701383841

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  10 in total

Review 1.  Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.

Authors:  Salma Afifi; Angela Michael; Alexander Lesokhin
Journal:  Ann Pharmacother       Date:  2016-04-15       Impact factor: 3.154

2.  CD38 expression as response of hematopoietic system to cancer.

Authors:  Işil Albeniz; Ozlem Demir-Coşkun; Leyla Türker-Şener; Aycan Baş; Oktar Asoğlu; Rüstem Nurten
Journal:  Oncol Lett       Date:  2011-05-16       Impact factor: 2.967

3.  Isolation of hematopoietic stem cells and the effect of CD38 expression during the early erythroid progenitor cell development process.

Authors:  Işil Albenız; Leyla Türker-Şener; Aycan Baş; Ibrahim Kalelıoğlu; Rüstem Nurten
Journal:  Oncol Lett       Date:  2011-10-21       Impact factor: 2.967

4.  c-Cbl tyrosine kinase-binding domain mutant G306E abolishes the interaction of c-Cbl with CD38 and fails to promote retinoic acid-induced cell differentiation and G0 arrest.

Authors:  Miaoqing Shen; Andrew Yen
Journal:  J Biol Chem       Date:  2009-07-27       Impact factor: 5.157

5.  c-Cbl interacts with CD38 and promotes retinoic acid-induced differentiation and G0 arrest of human myeloblastic leukemia cells.

Authors:  Miaoqing Shen; Andrew Yen
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

Review 6.  Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Authors:  Philippe Moreau; Niels W C J van de Donk; Jesus San Miguel; Henk Lokhorst; Hareth Nahi; Dina Ben-Yehuda; Michele Cavo; Gordon Cook; Michel Delforge; Hermann Einsele; Sonja Zweegman; Heinz Ludwig; Christoph Driessen; Antonio Palumbo; Thierry Facon; Torben Plesner; Meletios Dimopoulos; Pia Sondergeld; Pieter Sonneveld; María-Victoria Mateos
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

Review 7.  New developments in the treatment of multiple myeloma - clinical utility of daratumumab.

Authors:  Cian McEllistrim; Janusz Krawczyk; Michael E O'Dwyer
Journal:  Biologics       Date:  2017-04-11

8.  CCL2 associated with CD38 expression during ex vivo expansion in human cord blood-derived hematopoietic stem cells.

Authors:  Chao-Ling Yao; Poyin Huang; Tsai-Chi Liu; Yung-Kai Lin; Ching-Yun Chen; Yi-Ting Lai; Tzu Yun Chin; Tsung-Yu Tseng; Yi-Chiung Hsu
Journal:  Aging (Albany NY)       Date:  2021-08-10       Impact factor: 5.682

Review 9.  Overcoming Drug Interference in Transfusion Testing: A Spotlight on Daratumumab.

Authors:  Marilyn T Nedumcheril; Robert A DeSimone; Sabrina E Racine-Brzostek; Ok Kyong Chaekal; Ljiljana V Vasovic
Journal:  J Blood Med       Date:  2021-05-25

10.  Purification of NAD+ glycohydrolase from human serum.

Authors:  Ozlem Coşkun; Rüstem Nurten
Journal:  Oncol Lett       Date:  2013-05-08       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.